Literature DB >> 10551686

ST-segment monitoring with continuous 12-lead ECG improves early risk stratification in patients with chest pain and ECG nondiagnostic of acute myocardial infarction.

T Jernberg1, B Lindahl, L Wallentin.   

Abstract

OBJECTIVES: The purpose of this study was to evaluate the prognostic importance of ischemic episodes detected by ST-segment monitoring with continuous 12-lead electrocardiography (ECG) in a nonselected coronary care unit (CCU) population with chest pain and ECG nondiagnostic of acute myocardial infarction (AMI).
BACKGROUND: Patients with chest pain and ECG nondiagnostic of AMI constitute a heterogeneous group concerning both diagnosis and prognosis. Continuous 12-lead ECG is a rather new method not thoroughly studied in this population.
METHODS: The ST-segment monitoring with continuous 12-lead ECG was performed for 12 h in 630 consecutive patients admitted to CCU due to chest pain and a nondiagnostic ECG, i.e., no ST-segment elevations. An ST-episode was defined as a transient ST-segment depression or elevation of at least 0.10 mV. The median follow-up time was six months.
RESULTS: A total of 176 ST-episodes occurred in 100 (15.9%) patients. The median duration and maximal ST-segment deviation in patients with ST-episodes were 80 min and 0.20 mV, respectively. Presence of ST-episodes predicted worse outcome concerning cardiac death and cardiac death or myocardial infarction (MI) (log-rank p < 0.001). At 30 day follow-up procedure, 10% versus 1.5% died from cardiac causes or had an MI in the group with and without ST-episodes, respectively. In a multivariate analysis, only troponin T > or = 0.10 microg/l and the presence of ST-episodes came out as independent predictors of cardiac death or MI.
CONCLUSIONS: Continuous 12-lead ECG monitoring provides prognostic information on-line and considerably improves early risk stratification in patients with ECG nondiagnostic of AMI and symptoms suggestive of acute coronary syndrome.

Entities:  

Mesh:

Year:  1999        PMID: 10551686     DOI: 10.1016/s0735-1097(99)00370-8

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  7 in total

1.  New advances in the management of acute coronary syndromes: 1. Matching treatment to risk.

Authors:  D Fitchett; S Goodman; A Langer
Journal:  CMAJ       Date:  2001-05-01       Impact factor: 8.262

2.  Prognostic value of continuous ST-segment monitoring in patients with non-ST-segment elevation acute coronary syndromes.

Authors:  Carlos Aguiar; Jorge Ferreira; Ricardo Seabra-Gomes
Journal:  Ann Noninvasive Electrocardiol       Date:  2002-01       Impact factor: 1.468

3.  Does continuous ST-segment monitoring add prognostic information to the TIMI, PURSUIT, and GRACE risk scores?

Authors:  Pedro Carmo; Jorge Ferreira; Carlos Aguiar; António Ferreira; Luís Raposo; Pedro Gonçalves; João Brito; Aniceto Silva
Journal:  Ann Noninvasive Electrocardiol       Date:  2011-07       Impact factor: 1.468

4.  FRISC score for selection of patients for an early invasive treatment strategy in unstable coronary artery disease.

Authors:  B Lagerqvist; E Diderholm; B Lindahl; S Husted; F Kontny; E Ståhle; E Swahn; P Venge; A Siegbahn; L Wallentin
Journal:  Heart       Date:  2005-08       Impact factor: 5.994

5.  Observer variability and optimal criteria of transient ischemia during ST monitoring with continuous 12-lead ECG.

Authors:  Tomas Jernberg; Jörgen Cronblad; Bertil Lindahl; Lars Wallentin
Journal:  Ann Noninvasive Electrocardiol       Date:  2002-07       Impact factor: 1.468

6.  Electrocardiographic predictors of sudden and non-sudden cardiac death in patients with ischemic cardiomyopathy.

Authors:  Salah S Al-Zaiti; James A Fallavollita; John M Canty; Mary G Carey
Journal:  Heart Lung       Date:  2014-07-02       Impact factor: 2.210

7.  Diagnostic accuracy of a new cardiac electrical biomarker for detection of electrocardiogram changes suggestive of acute myocardial ischemic injury.

Authors:  David M Schreck; Robert D Fishberg
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-10-07       Impact factor: 1.468

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.